CRB2117
/ China Resources Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 17, 2026
CRB2117, a Novel GPC3/CD3 T-Cell Engager Demonstrates Potent Antitumor Efficacy and Mitigated CRS Risk in Hepatocellular Carcinoma
(ESMO 2026)
- No abstract available
Clinical • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3
1 to 1
Of
1
Go to page
1